Browsing by Author "Delic, Dragan (55886413300)"
Now showing 1 - 20 of 20
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Characteristics of patients dying from acute viral hepatitis in Serbia(2011) ;Svirtlih, Neda (6603664119) ;Delic, Dragan (55886413300) ;Simonovic, Jasmina (6507086058) ;Dokic, Ljubisa (6602526803) ;Gvozdenovic, Eleonora (14832449700) ;Dulovic, Olga (6602485522) ;Nesic, Zorica (6701752615)Boricic, Ivan (6603959716)Background/aims: Background/aims: Acute viral hepatitis is complicated rarely with severe liver failure due to many factors associated with the etiology, patient age, and time of development of hepatic encephalopathy, etc. The aim of this study was to identify some of the clinical and laboratory features associated with a fatal outcome in patients dying from acute viral hepatitis in Serbia. Methods: Clinical and laboratory data from 47 patients hospitalized from January 1989 - December 2006 were reviewed retrospectively. Serological tests for hepatitis A, B, C, D, and E viruses, herpes simplex viruses, cytomegalovirus, and Epstein-Barr virus were done. Histological features were assessed from 35 liver tissues. The electronic base, SPSS for Windows (version 11.0), was used for statistical analysis. Results: The majority of the patients had alanine aminotransferase (ALT) >20x the normal value, serum bilirubin >300μmol/L, prothrombin time >25 seconds (s), and white blood cell count >12 × 10 9/L. Regression analysis revealed activity of alanine aminotransferase >20x the normal value to be associated with fulminant (p=0.015) and serum bilirubin concentration with subfulminant hepatitis (p=0.008). Hepatitis B virus was the most commonly detected virus (70%). Massive hepatocyte necrosis vs. sub-massive with bridging necrosis were found to be independent of clinical presentation. Conclusions: Hepatitis B virus infection, severe impairment of liver function tests, and confluent hepatocyte necrosis and infection characterize patients dying from acute viral hepatitis in Serbia. High activity of alanine aminotransferase reflects rapid and extensive acute viral liver injury, while deep jaundice is more common in a protracted course of the disease. - Some of the metrics are blocked by yourconsent settings
Publication Hepatitis C virus genotypes in Serbia and Montenegro: The prevalence and clinical significance(2007) ;Svirtlih, Neda (6603664119) ;Delic, Dragan (55886413300) ;Simonovic, Jasmina (6507086058) ;Jevtovic, Djordje (55410443900) ;Dokic, Ljubisa (6602526803) ;Gvozdenovic, Eleonora (14832449700) ;Boricic, Ivan (6603959716) ;Terzic, Dragica (15835708300) ;Pavic, Sladjana (6603595864) ;Neskovic, Gorana (6508293958) ;Zerjav, Sonja (6603691730)Urban, Vladimir (57219892421)Aim: To investigate the prevalence of hepatitis C virus (HCV) genotypes in Serbia and Montenegro and their influence on some clinical characteristics in patients with chronic HCV infection. Methods: A total of 164 patients was investigated. Complete history route of infection, assessment of alcohol consumption, an abdominal ultrasound, standard biochemical tests and liver biopsy were done. Gene sequencing of 5′ NTR type-specific PCR or commercial kits was performed for HCV genotyping and subtyping. The SPSS for Windows (version 10.0) was used for univariate regression analysis with further multivariate analysis. Results: The genotypes 1, 2, 3, 4, 1b3a and 1b4 were present in 57.9%, 3.7%, 23.2%, 6.7%, 6.7% and 1.8% of the patients, respectively. The genotype 1 (mainly the subtype 1b) was found to be independent of age in subjects older than 40 years, high viral load, more severe necro-inflammatory activity, advanced stage of fibrosis, and absence of intravenous drug abuse. The genotype 3a was associated with intravenous drug abuse and the age below 40. Multivariate analysis demonstrated age over 40 and intravenous drug abuse as the positive predictive factors for the genotypes lb and 3a, respectively. Conclusion: In Serbia and Montenegro, the genotypes 1b and 3a predominate in patients with chronic HCV infection. The subtype lb is characteristic of older patients, while the genotype 3a is common in drug abusers. Association of the subtype lb with advanced liver disease, higher viral load and histological activity suggests earlier infection with this genotype and eventually its increased pathogenicity. © 2007 The WJG Press. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication IL-28B genotypes as predictors of long-term outcome in patients with hepatitis C-related severe liver injury(2019) ;Jordovic, Jelena (57190498051) ;Simonovic-Babic, Jasmina (8313556500) ;Gasic, Vladimir (57095898600) ;Kotur, Nikola (54961068500) ;Zukic, Branka (26030757000) ;Pavlovic, Sonja (7006514877) ;Lazarevic, Ivana (23485928400) ;Karalic, Danijela (57403944300) ;Katanic, Natasa (57190964860) ;Nikolic, Natasa (58288723700) ;Urosevic, Aleksandar (58075718100) ;Nestorov, Jelena (57219044106) ;Delic, Dragan (55886413300)Bojovic, Ksenija (6505585757)Introduction: Patients with severe fibrosis or cirrhosis are at high risk for liver-related complications, even after successful antiviral treatment and/or regression of fibrosis. These are the first published results concerning the role of IL-28B genotypes as predictors of the durability of sustained virological response (SVR) and long-term outcome, in patients with baseline severe fibrosis and cirrhosis caused by hepatitis C (HCV) infection. Methodology: Genetic testing for three different single nucleotide polymorphisms (SNP) near the IL28B gene, rs12979860, rs12980275 and rs8099917, was performed in 42 patients with HCV-related advanced fibrosis and cirrhosis, who achieved SVR after successful interferon-based treatment. Baseline clinical and laboratory parameters were analysed, as well as IL28B genotype association with late virological relapse, fibrosis progression and clinical outcomes. Results: The most prevalent genotypes in all three tested SNP positions were: CCrs12979860 genotype in 69% of patients, GTrs8099917 in 78.6% and GGrs12980275 in 47.6% of patients. The presence of IL28B CCrs12979860 genotype was identified as a negative predictor of late virological relapse. Further analysis did not confirm the association of other IL28B genotypes with the progression of fibrosis and clinical outcomes. Conclusions: Varying long-term prognosis in patients with HCV-related severe fibrosis and cirrhosis is due to multiple interactions between host genetic factors, virus and environment. These are first published results demonstrating the significance of IL28B CCrs12979860 genotype as a negative predictor of late virological relapse. A further investigation concerning genetic factors is necessary to identify patients under risk for late relapse, complications and unfavorable outcomes, so that they can be reevaluated and offered new treatment options. © 2019 Jordovic et al. - Some of the metrics are blocked by yourconsent settings
Publication IL-28B genotypes as predictors of long-term outcome in patients with hepatitis C-related severe liver injury(2019) ;Jordovic, Jelena (57190498051) ;Simonovic-Babic, Jasmina (8313556500) ;Gasic, Vladimir (57095898600) ;Kotur, Nikola (54961068500) ;Zukic, Branka (26030757000) ;Pavlovic, Sonja (7006514877) ;Lazarevic, Ivana (23485928400) ;Karalic, Danijela (57403944300) ;Katanic, Natasa (57190964860) ;Nikolic, Natasa (58288723700) ;Urosevic, Aleksandar (58075718100) ;Nestorov, Jelena (57219044106) ;Delic, Dragan (55886413300)Bojovic, Ksenija (6505585757)Introduction: Patients with severe fibrosis or cirrhosis are at high risk for liver-related complications, even after successful antiviral treatment and/or regression of fibrosis. These are the first published results concerning the role of IL-28B genotypes as predictors of the durability of sustained virological response (SVR) and long-term outcome, in patients with baseline severe fibrosis and cirrhosis caused by hepatitis C (HCV) infection. Methodology: Genetic testing for three different single nucleotide polymorphisms (SNP) near the IL28B gene, rs12979860, rs12980275 and rs8099917, was performed in 42 patients with HCV-related advanced fibrosis and cirrhosis, who achieved SVR after successful interferon-based treatment. Baseline clinical and laboratory parameters were analysed, as well as IL28B genotype association with late virological relapse, fibrosis progression and clinical outcomes. Results: The most prevalent genotypes in all three tested SNP positions were: CCrs12979860 genotype in 69% of patients, GTrs8099917 in 78.6% and GGrs12980275 in 47.6% of patients. The presence of IL28B CCrs12979860 genotype was identified as a negative predictor of late virological relapse. Further analysis did not confirm the association of other IL28B genotypes with the progression of fibrosis and clinical outcomes. Conclusions: Varying long-term prognosis in patients with HCV-related severe fibrosis and cirrhosis is due to multiple interactions between host genetic factors, virus and environment. These are first published results demonstrating the significance of IL28B CCrs12979860 genotype as a negative predictor of late virological relapse. A further investigation concerning genetic factors is necessary to identify patients under risk for late relapse, complications and unfavorable outcomes, so that they can be reevaluated and offered new treatment options. © 2019 Jordovic et al. - Some of the metrics are blocked by yourconsent settings
Publication Letters to the editor(2008) ;Svirtlih, Neda (6603664119) ;Delic, Dragan (55886413300) ;Simonovic, Jasmina (6507086058)Boricic, Ivan (6603959716)[No abstract available] - Some of the metrics are blocked by yourconsent settings
Publication Older age at the time of liver biopsy is the important risk factor for advanced fibrosis in patients with chronic hepatitis C(2007) ;Svirtlih, Neda (6603664119) ;Jevtovic, Djordje (55410443900) ;Simonovic, Jasmina (6507086058) ;Delic, Dragan (55886413300) ;Dokic, Ljubisa (6602526803) ;Gvozdenovic, Eleonora (14832449700) ;Boricic, Ivan (6603959716) ;Nesic, Zorica (6701752615) ;Neskovic, Gorana (6508293958)Urban, Vladimir (57219892421)Background/Aims: Progression of chronic hepatitis C depends on the host and viral characteristics, duration of infection, co-infection with other viruses, etc. In this study, some of demographic, epidemiological and viral data as risk factors for a degree of liver fibrosis were evaluated. Methodology: A total of 144 patients was investigated (89 males, ages from 16-65 years) classified into two groups, with fibrosis scores 0-3 and 4-6, using the Ishak scoring system. Significant variables were entered into univariate logistic regression model and further multivariate analysis was performed. Results: There were 64% and 36% of patients with fibrosis scores 0-3 and 4-6, respectively. Gender, moderate to heavy alcohol abuse and high viral RNA were equally distributed between both groups. In univariate analysis, the age older than 40, history of intravenous drug abuse, and the genotype 1b were independently associated with different fibrosis scores. Multivariate regression analysis revealed ages older than 40 as the positive (p<0.001), and younger than 40 as the negative predictive factors for fibrosis scores 4-6 and 0-3 (p<0.001), respectively. Conclusions: Our results indicate the age over 40 at the time of liver biopsy as the important risk factor for advanced liver disease in chronic hepatitis C according to fibrosis scores. © H.G.E. Update Medical Publishing S.A. - Some of the metrics are blocked by yourconsent settings
Publication Oral teicoplanin for successful treatment of severe refractory clostridium difficile infection(2015) ;Popovic, Natasa (57214680239) ;Korac, Milos (10040016700) ;Nesic, Zorica (6701752615) ;Milosevic, Branko (57204639427) ;Urosevic, Aleksandar (58075718100) ;Jevtovic, Djordje (55410443900) ;Pelemis, Mijomir (6507978433) ;Delic, Dragan (55886413300) ;Prostran, Milica (7004009031)Milosevic, Ivana (58456808200)Introduction: Clostridium difficile is the leading cause of hospital-acquired diarrhoea. There is no defined protocol for treating severe Clostridium difficile infection (CDI) refractory to vancomycin or vancomycin and metronidazole combination therapy. The aim of this study was to evaluate the rate of clinical cure, time to resolution of diarrhoea and recurrence rate in patients with severe refractory CDI treated with oral teicoplanin. Methodology: A one-year prospective study was carried out in the Clinic for Infectious and Tropical Diseases, Clinical Center Serbia. Patients with severe and complicated CDI who failed to respond to oral vancomycin and intravenous metronidazole combination therapy were enrolled. They were given oral teicoplanin 100 mg bi-daily. Patients were followed for recurrence for eight weeks. Results: Nine patients with a mean age of 70.8±9.4 years were analyzed. All patients had pseudomembranous colitis, and five had complicated disease. In four patients intracolonic delivery of vancomycin was also performed in addition to oral vancomycin and intravenous metronidazole prior to initiating teicoplanin, but without improvement. After teicoplanin initiation all patients achieved clinical cure. The mean time to resolution of diarrhoea after teicoplanin introduction was 6.3±4.5 days. There was no statistically significant difference in time to resolution of diarrhoea according to initial leucocyte count, age over 65 years, the presence of ileus, complicated disease and the use of concomitant antibiotic therapy (p = 0.652, 0,652, 0.374, 0.374, and 0,548, respectively). None of the patients experienced recurrence. Conclusions: Oral teicoplanin might be a potential treatment for severe and complicated refractory CDI, but further studies are required. © 2015 Popovic et al. - Some of the metrics are blocked by yourconsent settings
Publication Oral teicoplanin for successful treatment of severe refractory clostridium difficile infection(2015) ;Popovic, Natasa (57214680239) ;Korac, Milos (10040016700) ;Nesic, Zorica (6701752615) ;Milosevic, Branko (57204639427) ;Urosevic, Aleksandar (58075718100) ;Jevtovic, Djordje (55410443900) ;Pelemis, Mijomir (6507978433) ;Delic, Dragan (55886413300) ;Prostran, Milica (7004009031)Milosevic, Ivana (58456808200)Introduction: Clostridium difficile is the leading cause of hospital-acquired diarrhoea. There is no defined protocol for treating severe Clostridium difficile infection (CDI) refractory to vancomycin or vancomycin and metronidazole combination therapy. The aim of this study was to evaluate the rate of clinical cure, time to resolution of diarrhoea and recurrence rate in patients with severe refractory CDI treated with oral teicoplanin. Methodology: A one-year prospective study was carried out in the Clinic for Infectious and Tropical Diseases, Clinical Center Serbia. Patients with severe and complicated CDI who failed to respond to oral vancomycin and intravenous metronidazole combination therapy were enrolled. They were given oral teicoplanin 100 mg bi-daily. Patients were followed for recurrence for eight weeks. Results: Nine patients with a mean age of 70.8±9.4 years were analyzed. All patients had pseudomembranous colitis, and five had complicated disease. In four patients intracolonic delivery of vancomycin was also performed in addition to oral vancomycin and intravenous metronidazole prior to initiating teicoplanin, but without improvement. After teicoplanin initiation all patients achieved clinical cure. The mean time to resolution of diarrhoea after teicoplanin introduction was 6.3±4.5 days. There was no statistically significant difference in time to resolution of diarrhoea according to initial leucocyte count, age over 65 years, the presence of ileus, complicated disease and the use of concomitant antibiotic therapy (p = 0.652, 0,652, 0.374, 0.374, and 0,548, respectively). None of the patients experienced recurrence. Conclusions: Oral teicoplanin might be a potential treatment for severe and complicated refractory CDI, but further studies are required. © 2015 Popovic et al. - Some of the metrics are blocked by yourconsent settings
Publication Prevalence of hepatitis B virus MHR mutations and their correlation with genotypes and antiviral therapy in chronically infected patients in Serbia(2010) ;Lazarevic, Ivana (23485928400) ;Cupic, Maja (15730255400) ;Delic, Dragan (55886413300) ;Svirtlih, Neda Stojkovic (6603664119) ;Simonovic, Jasmina (6507086058)Jovanovic, Tanja (26642921700)Understanding the prevalence and diversity of HBsAg variants in a population is fundamental to assay design and planning vaccination programs. It has been shown that mutations within the S gene, caused by selection or natural variation, can lead to false-negative results in assays for HBsAg, or have clinical implications, such as evading anti-HBV immunoglobulin therapy or vaccine-induced immunity. The region of HBsAg where most of these mutations occur is known as the major hydrophilic region (MHR). The aim of this study was to determine the prevalence and mutational patterns of MHR mutations in patients with chronic hepatitis B, and their correlation with patient characteristics, viral factors and antiviral therapy. The study comprised 164 plasma samples from patients with chronic hepatitis B, of which, 34.8% were on long-term lamivudine monotherapy. Direct sequencing of part of the S/pol gene was used for identification of HBsAg mutations, HBV genotypes, subgenotypes and HBsAg subtypes. The overall frequency of MHR mutations was 22.6%, but it varied significantly between untreated and treated patients (16.8% vs. 33.3%). The most frequent substitution was at position 120 (9.1%) whereas the most common vaccine-escape position, 145, was affected in 1.8% of isolates. The presence of MHR mutations was correlated with genotype D, subgenotype D3, and ayw2/ayw3 HBsAg subtypes and to older age (>40 years). It is concluded that natural viral variability present in a geographical region, duration of infection, and antiviral therapy are among the major factors associated with the occurrence of MHR mutations. © 2010 Wiley-Liss, Inc. - Some of the metrics are blocked by yourconsent settings
Publication Prevalence of hepatitis B virus MHR mutations and their correlation with genotypes and antiviral therapy in chronically infected patients in Serbia(2010) ;Lazarevic, Ivana (23485928400) ;Cupic, Maja (15730255400) ;Delic, Dragan (55886413300) ;Svirtlih, Neda Stojkovic (6603664119) ;Simonovic, Jasmina (6507086058)Jovanovic, Tanja (26642921700)Understanding the prevalence and diversity of HBsAg variants in a population is fundamental to assay design and planning vaccination programs. It has been shown that mutations within the S gene, caused by selection or natural variation, can lead to false-negative results in assays for HBsAg, or have clinical implications, such as evading anti-HBV immunoglobulin therapy or vaccine-induced immunity. The region of HBsAg where most of these mutations occur is known as the major hydrophilic region (MHR). The aim of this study was to determine the prevalence and mutational patterns of MHR mutations in patients with chronic hepatitis B, and their correlation with patient characteristics, viral factors and antiviral therapy. The study comprised 164 plasma samples from patients with chronic hepatitis B, of which, 34.8% were on long-term lamivudine monotherapy. Direct sequencing of part of the S/pol gene was used for identification of HBsAg mutations, HBV genotypes, subgenotypes and HBsAg subtypes. The overall frequency of MHR mutations was 22.6%, but it varied significantly between untreated and treated patients (16.8% vs. 33.3%). The most frequent substitution was at position 120 (9.1%) whereas the most common vaccine-escape position, 145, was affected in 1.8% of isolates. The presence of MHR mutations was correlated with genotype D, subgenotype D3, and ayw2/ayw3 HBsAg subtypes and to older age (>40 years). It is concluded that natural viral variability present in a geographical region, duration of infection, and antiviral therapy are among the major factors associated with the occurrence of MHR mutations. © 2010 Wiley-Liss, Inc. - Some of the metrics are blocked by yourconsent settings
Publication Reduced quality of life in patients with chronic viral liver disease as assessed by SF12 questionnaire(2008) ;Svirtlih, Neda (6603664119) ;Pavic, Sladjana (6603595864) ;Terzic, Dragica (15835708300) ;Delic, Dragan (55886413300) ;Simonovic, Jasmina (6507086058) ;Gvazdenovic, Eleonora (26647471200)Boricic, Ivan (6603959716)Background & Aim. Quality of life may be reduced in patients with chronic liver diseases. The purpose of this study was to assess the impact of chronic viral liver disease on health-related quality of life (HRQOL). Patients and methods. Quality of life was prospectively investigated in 227 patients with chronic viral liver disease and 75 controls. The generic Short Form 12 questionnaire was applied to measure the HRQOL. Mental and physical component scores were expressed as numeric and categorical values (presence/absence of disability). The electronic database (SPSS for Windows) was used for statistical analysis with 95% confidence intervals. Results. Mental and physical numeric and categorical scores for the absence of disability were significantly worse in patients compared with controls. Patients were a negative predictive factor for the absence of disability on both mental and physical components while the physical component was the significant factor in multivariate regression analysis (p =0.000). There was no difference in HRQOL scores among patients with hepatitis C or B virus infection. Mental and physical numeric scores were lower in patients with cirrhosis. Liver cirrhosis predicted lower components of the absence of disability in comparison to chronic hepatitis more influencing the physical component (p =0.003). Conclusions. Chronic viral liver disease reduces and predicts a lower quality of life in comparison to a healthy population impairing more the physical component. Hepatitis viruses do not influence differently the quality of life. Liver cirrhosis has a higher negative impact on the quality of life than chronic hepatitis, especially relating to a physical component. - Some of the metrics are blocked by yourconsent settings
Publication Seroprevalence and risk factors for hepatitis C virus infection among blood donors in Serbia: A multicentre study(2015) ;Mitrovic, Nikola (55110096400) ;Delic, Dragan (55886413300) ;Markovic-Denic, Ljiljana (55944510900) ;Jovicic, Milica (56915792700) ;Popovic, Natasa (57214680239) ;Bojovic, Ksenija (6505585757) ;Simonovic Babic, Jasmina (8313556500)Svirtlih, Neda (6603664119)Background: The epidemiological characteristics of hepatitis C virus (HCV) infection have not yet been described in Serbia. Aims: To determine the prevalence of anti-HCV-positive individuals among first-time blood donors and the risk factors for hepatitis C transmission. Methods: A multicentre case-control study nested within a prospective cohort study was conducted at 10 main transfusion centres in Serbia in 2013 and 27,160 blood donors who gave blood for the first time were included. Blood donors with confirmed anti-HCV positivity and seronegative controls were enrolled to determine the risk factors. Results: Of 27,160 blood donors 52 were anti-HCV-positive; seroprevalence was 0.19%. By univariate analysis, marital status, educational level, drug use, previous transfusion, tattooing, non-use of condoms and number of sexual partners, were risk factors for hepatitis C. In the final multivariate analysis, three factors remained independently predictive: drug use, tattooing and previous blood transfusion. In total, 87.5% of cases had at least one of the risk factors for HCV transmission; 20.9% presumed that they knew when the infection occurred. Conclusion: HCV seroprevalence in Serbia is higher than in developed European countries. Preventive measures need to be directed towards drug use and tattooing facilities. The admission questionnaire for blood donors should be improved. © 2015 Editrice Gastroenterologica Italiana S.r.l. - Some of the metrics are blocked by yourconsent settings
Publication Significance of UGT1A1∗28 genotype in patients with advanced liver injury caused by chronic hepatitis C(2019) ;Jordovic, Jelena (57190498051) ;Bojovic, Ksenija (6505585757) ;Simonovic-Babic, Jasmina (8313556500) ;Gasic, Vladimir (57095898600) ;Kotur, Nikola (54961068500) ;Zukic, Branka (26030757000) ;Vukovic, Marija (57201985678) ;Pavlovic, Sonja (7006514877) ;Lazarevic, Ivana (23485928400) ;Bekic, Ivana (58950933100) ;Nikolic, Natasa (58288723700) ;Uroševic, Aleksandar (58075718100) ;Mitrovic, Nikola (55110096400)Delic, Dragan (55886413300)Background: Chronic hepatitis C (CHC) is a significant cause of liver related morbidity and mortality worldwide. The role of genetics in the host response to hepatitis C virus is not elucidated. Genetic variations in UGT1A1 gene are the most common cause of hereditary unconjugated hyperbilirubinemia-Gilbert syndrome. This is the first study investigating the association of UGT1A1 TA repeats promoter genotypes with the degree of liver injury, viremia and biochemical markers in CHC patients with advanced liver injury and late virological relapse. Methods: Genetic testing of UGT1A1 TA repeats promoter genotypes was performed in 42 CHC patients with advanced fibrosis and cirrhosis who achieved sustained virological response and 42 healthy blood donors. CHC patients were evaluated for clinical findings, laboratory tests and imaging. Results: UGT1A1∗28 genotype (7/7 TA repeats) was observed in 23.8% CHC patients and 16.7% healthy controls with no significant difference in genotype frequencies (p=0.49). Pretreatment levels of ferritin and bilirubin were associated with the presence of UGT1A1∗28 genotype, indicating its potential as a predictive marker. However, in our study, there was no correlation of UGT1A1∗28 genotype with the degree of fibrosis or viremia. During antiviral treatment, dose reductions and treatment interruptions, as well as treatment success and occurrence of late virological relapse were not related to the presence of UGT1A1∗28 genotype in CHC patients with severe liver injury. Conclusions: Frequencies of UGT1A1∗28 genotype are high in both Serbian CHC patients and healthy subjects. The presence of UGT1A1∗28 genotype was not associated with ribavirin-related adverse effects and had no effect on long term outcome in CHC patients. © 2019 Jelena Jordovic et al., published by Sciendo 2019. - Some of the metrics are blocked by yourconsent settings
Publication Significance of UGT1A1∗28 genotype in patients with advanced liver injury caused by chronic hepatitis C(2019) ;Jordovic, Jelena (57190498051) ;Bojovic, Ksenija (6505585757) ;Simonovic-Babic, Jasmina (8313556500) ;Gasic, Vladimir (57095898600) ;Kotur, Nikola (54961068500) ;Zukic, Branka (26030757000) ;Vukovic, Marija (57201985678) ;Pavlovic, Sonja (7006514877) ;Lazarevic, Ivana (23485928400) ;Bekic, Ivana (58950933100) ;Nikolic, Natasa (58288723700) ;Uroševic, Aleksandar (58075718100) ;Mitrovic, Nikola (55110096400)Delic, Dragan (55886413300)Background: Chronic hepatitis C (CHC) is a significant cause of liver related morbidity and mortality worldwide. The role of genetics in the host response to hepatitis C virus is not elucidated. Genetic variations in UGT1A1 gene are the most common cause of hereditary unconjugated hyperbilirubinemia-Gilbert syndrome. This is the first study investigating the association of UGT1A1 TA repeats promoter genotypes with the degree of liver injury, viremia and biochemical markers in CHC patients with advanced liver injury and late virological relapse. Methods: Genetic testing of UGT1A1 TA repeats promoter genotypes was performed in 42 CHC patients with advanced fibrosis and cirrhosis who achieved sustained virological response and 42 healthy blood donors. CHC patients were evaluated for clinical findings, laboratory tests and imaging. Results: UGT1A1∗28 genotype (7/7 TA repeats) was observed in 23.8% CHC patients and 16.7% healthy controls with no significant difference in genotype frequencies (p=0.49). Pretreatment levels of ferritin and bilirubin were associated with the presence of UGT1A1∗28 genotype, indicating its potential as a predictive marker. However, in our study, there was no correlation of UGT1A1∗28 genotype with the degree of fibrosis or viremia. During antiviral treatment, dose reductions and treatment interruptions, as well as treatment success and occurrence of late virological relapse were not related to the presence of UGT1A1∗28 genotype in CHC patients with severe liver injury. Conclusions: Frequencies of UGT1A1∗28 genotype are high in both Serbian CHC patients and healthy subjects. The presence of UGT1A1∗28 genotype was not associated with ribavirin-related adverse effects and had no effect on long term outcome in CHC patients. © 2019 Jelena Jordovic et al., published by Sciendo 2019. - Some of the metrics are blocked by yourconsent settings
Publication The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C(2013) ;Lazarevic, Ivana (23485928400) ;Djordjevic, Jelena (57217077627) ;Cupic, Maja (15730255400) ;Karalic, Danijela (57403944300) ;Delic, Dragan (55886413300) ;Svirtlih, Neda (6603664119) ;Simonovic, Jasmina (6507086058) ;Svorcan, Petar (8950517800) ;Milic, Natasa (7003460927)Jovanovic, Tanja (26642921700)Background: Three single nucleotide polymorphisms (SNPs) near IL28B gene were shown to be highly predictive of sustained virological response (SVR) in patients with chronic hepatitis C virus (HCV) infection. Objectives: This study attempted to demonstrate the role of single and combined IL28B polymorphisms (rs8099917, rs12979860 and rs12980275) and other host and viral factors in predicting response to treatment, in Caucasian patients infected with HCV genotype 1. Study design: The IL28B genotypes at 3 SNPs were determined in 106 patients who underwent standard 48-week therapy and out of which 55.7% achieved SVR. Results: Patients carrying genotypes CCrs12979860 or AArs12980275 were 3.5 and 3 times more likely to achieve SVR, respectively. Genotypes GGrs8099917 and TTrs12979860 were identified as predictors of treatment failure. The presence of IL28B profiles including at least one of the favourable genotypes was identified as the most important factor associated with SVR, followed by younger age and lower grade of histological activity. Of all patients who achieved SVR, 88.1% was carrying one of these IL28B profiles. The strongest PPV of single SNPs for achieving SVR was observed for CCrs12979860 (76.9%). The presence of GGrs8099917 showed the strongest NPV of 85.7%. The correlation of SNPs with other host and viral factors revealed association of TTrs8099917 and lower AST levels. Conclusions: Results of this study confirm that all investigated IL28B polymorphisms are associated with treatment response and that presence of any of the favourable IL28B genotypes can be considered independent pretreatment determinant of the effectiveness of therapy. © 2013 Elsevier B.V. - Some of the metrics are blocked by yourconsent settings
Publication The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C(2013) ;Lazarevic, Ivana (23485928400) ;Djordjevic, Jelena (57217077627) ;Cupic, Maja (15730255400) ;Karalic, Danijela (57403944300) ;Delic, Dragan (55886413300) ;Svirtlih, Neda (6603664119) ;Simonovic, Jasmina (6507086058) ;Svorcan, Petar (8950517800) ;Milic, Natasa (7003460927)Jovanovic, Tanja (26642921700)Background: Three single nucleotide polymorphisms (SNPs) near IL28B gene were shown to be highly predictive of sustained virological response (SVR) in patients with chronic hepatitis C virus (HCV) infection. Objectives: This study attempted to demonstrate the role of single and combined IL28B polymorphisms (rs8099917, rs12979860 and rs12980275) and other host and viral factors in predicting response to treatment, in Caucasian patients infected with HCV genotype 1. Study design: The IL28B genotypes at 3 SNPs were determined in 106 patients who underwent standard 48-week therapy and out of which 55.7% achieved SVR. Results: Patients carrying genotypes CCrs12979860 or AArs12980275 were 3.5 and 3 times more likely to achieve SVR, respectively. Genotypes GGrs8099917 and TTrs12979860 were identified as predictors of treatment failure. The presence of IL28B profiles including at least one of the favourable genotypes was identified as the most important factor associated with SVR, followed by younger age and lower grade of histological activity. Of all patients who achieved SVR, 88.1% was carrying one of these IL28B profiles. The strongest PPV of single SNPs for achieving SVR was observed for CCrs12979860 (76.9%). The presence of GGrs8099917 showed the strongest NPV of 85.7%. The correlation of SNPs with other host and viral factors revealed association of TTrs8099917 and lower AST levels. Conclusions: Results of this study confirm that all investigated IL28B polymorphisms are associated with treatment response and that presence of any of the favourable IL28B genotypes can be considered independent pretreatment determinant of the effectiveness of therapy. © 2013 Elsevier B.V. - Some of the metrics are blocked by yourconsent settings
Publication The prevalence and the risk factors for hepatitis C virus infection in Serbia(2018) ;Mitrovic, Nikola (55110096400) ;Delic, Dragan (55886413300) ;Markovic Denic, Ljiljana (55944510900) ;Nikolic, Natasa (58288723700) ;Bojovic, Ksenija (6505585757) ;Simonovic Babic, Jasmina (8313556500) ;Brmbolic, Branko (6701712863) ;Milosevic, Ivana (58456808200) ;Katanic, Natasa (57190964860)Barac, Aleksandra (55550748700)Introduction: The epidemiological characteristics of the hepatitis C virus (HCV) infection in Republic of Serbia have not been studied sufficiently so far. The aim of this study was to estimate the prevalence of anti-HCV positivity in the general population of Serbia and determine the risk factors for this infection. Methodology: Estimation of the prevalence was done using the median ratio method with data from several regional countries to a previously determined prevalence of anti-HCV positivity among volunteer blood donors of 0.19%. In order to determine the risk factors a matched case-control study was conducted of 106 subjects with confirmed HCV infection from the Clinic for Infectious and Tropical Diseases, Clinical Center of Serbia and the same number of hospital controls matched by sex and age. Results: The estimated prevalence of anti-HCV positivity in the general population of Serbia was 1.13% (95% CI: 1.0-1.26%). The most important predictive risk factors of HCV infection were: intravenous drug use (OR = 31.0; 95% CI: 3.7-259.6), blood transfusions (OR = 3.7; 95% CI: 1.6-8.7), invasive dental treatment (OR = 3.1; 95% CI: 1.4-6.8), and low level of education (OR = 2.2; 95% CI:1.1-4.7). A total of 91.5% of the persons with hepatitis C had at least one of the significant risk factors. Conclusion: The prevalence of anti-HCV positivity ranks Serbia in the range of mid-endemic European countries. Preventive measures should be directed at preventing drug use, on education about getting the infection, creating safe conditions for blood transfusions, and strict adherence to adopted practices in dentistry. © 2018 Mitrovic et al. - Some of the metrics are blocked by yourconsent settings
Publication The prevalence and the risk factors for hepatitis C virus infection in Serbia(2018) ;Mitrovic, Nikola (55110096400) ;Delic, Dragan (55886413300) ;Markovic Denic, Ljiljana (55944510900) ;Nikolic, Natasa (58288723700) ;Bojovic, Ksenija (6505585757) ;Simonovic Babic, Jasmina (8313556500) ;Brmbolic, Branko (6701712863) ;Milosevic, Ivana (58456808200) ;Katanic, Natasa (57190964860)Barac, Aleksandra (55550748700)Introduction: The epidemiological characteristics of the hepatitis C virus (HCV) infection in Republic of Serbia have not been studied sufficiently so far. The aim of this study was to estimate the prevalence of anti-HCV positivity in the general population of Serbia and determine the risk factors for this infection. Methodology: Estimation of the prevalence was done using the median ratio method with data from several regional countries to a previously determined prevalence of anti-HCV positivity among volunteer blood donors of 0.19%. In order to determine the risk factors a matched case-control study was conducted of 106 subjects with confirmed HCV infection from the Clinic for Infectious and Tropical Diseases, Clinical Center of Serbia and the same number of hospital controls matched by sex and age. Results: The estimated prevalence of anti-HCV positivity in the general population of Serbia was 1.13% (95% CI: 1.0-1.26%). The most important predictive risk factors of HCV infection were: intravenous drug use (OR = 31.0; 95% CI: 3.7-259.6), blood transfusions (OR = 3.7; 95% CI: 1.6-8.7), invasive dental treatment (OR = 3.1; 95% CI: 1.4-6.8), and low level of education (OR = 2.2; 95% CI:1.1-4.7). A total of 91.5% of the persons with hepatitis C had at least one of the significant risk factors. Conclusion: The prevalence of anti-HCV positivity ranks Serbia in the range of mid-endemic European countries. Preventive measures should be directed at preventing drug use, on education about getting the infection, creating safe conditions for blood transfusions, and strict adherence to adopted practices in dentistry. © 2018 Mitrovic et al. - Some of the metrics are blocked by yourconsent settings
Publication The significance of hepatitis B virus (HBV) genotypes for the disease and treatment outcome among patients with chronic hepatitis B in Serbia(2013) ;Milosevic, Ivana (58456808200) ;Delic, Dragan (55886413300) ;Lazarevic, Ivana (23485928400) ;Pavlovic, Ivana Pesic (55780084600) ;Korac, Milos (10040016700) ;Bojovic, Ksenija (6505585757)Jevtovic, Djordje (55410443900)Background: Hepatitis B virus (HBV) genotypes influence disease progression and treatment outcome. Objectives: To determine natural history and treatment outcome in patient chronically infected with HBV. Study design: A cohort study included 162 treatment naive patients with chronic HBV infection in order to analyze factors influencing natural history of infection and survival. Results: Genotype A was far less prevalent, detected in 14.2%. The prevalence of HbeAg+ serology of 60.8% among patients infected with genotype A was significantly higher then 30.9% recorded among those with genotype D (P=0.02). Even though patients from two genotypes subgroups had significantly different prevalence of HBeAg serology, their viral loads were similar at the time of diagnosis (2.90log10 and 3.31log10 HBV DNK IU/μl plasma, for genotypes A and D, respectively). The analyses of viral loads across three serologic patterns of chronic HBV infection were: for HBeAg+/HBeAb-, HbeAg-/HBAb+, and both "e" antigen and antibodies negative: 4.24, 2.67 and 2.69 log10IU/ml of HBV DNA IU/μl, respectively (P=0.01). Mean time to liver cirrhosis was 23.2±3.4 years and 15.1±8.4 years, for genotypes A and D, respectively (P=0.02). The overall estimated mean survival of patients with chronic HBV infection was 28.4 years, and was influenced by the stage of liver disease, but not by gender, age above 40, viral genotype and lamivudine therapy. Conclusions: Patients infected with genotype D had more rapid progression to ESLD regardless of levels of viral replication. All clinical and laboratory differences between genotypes did not affect survival of patients with chronic hepatitis B, regardless of lamivudine therapy. © 2013 Elsevier B.V. - Some of the metrics are blocked by yourconsent settings
Publication The significance of hepatitis B virus (HBV) genotypes for the disease and treatment outcome among patients with chronic hepatitis B in Serbia(2013) ;Milosevic, Ivana (58456808200) ;Delic, Dragan (55886413300) ;Lazarevic, Ivana (23485928400) ;Pavlovic, Ivana Pesic (55780084600) ;Korac, Milos (10040016700) ;Bojovic, Ksenija (6505585757)Jevtovic, Djordje (55410443900)Background: Hepatitis B virus (HBV) genotypes influence disease progression and treatment outcome. Objectives: To determine natural history and treatment outcome in patient chronically infected with HBV. Study design: A cohort study included 162 treatment naive patients with chronic HBV infection in order to analyze factors influencing natural history of infection and survival. Results: Genotype A was far less prevalent, detected in 14.2%. The prevalence of HbeAg+ serology of 60.8% among patients infected with genotype A was significantly higher then 30.9% recorded among those with genotype D (P=0.02). Even though patients from two genotypes subgroups had significantly different prevalence of HBeAg serology, their viral loads were similar at the time of diagnosis (2.90log10 and 3.31log10 HBV DNK IU/μl plasma, for genotypes A and D, respectively). The analyses of viral loads across three serologic patterns of chronic HBV infection were: for HBeAg+/HBeAb-, HbeAg-/HBAb+, and both "e" antigen and antibodies negative: 4.24, 2.67 and 2.69 log10IU/ml of HBV DNA IU/μl, respectively (P=0.01). Mean time to liver cirrhosis was 23.2±3.4 years and 15.1±8.4 years, for genotypes A and D, respectively (P=0.02). The overall estimated mean survival of patients with chronic HBV infection was 28.4 years, and was influenced by the stage of liver disease, but not by gender, age above 40, viral genotype and lamivudine therapy. Conclusions: Patients infected with genotype D had more rapid progression to ESLD regardless of levels of viral replication. All clinical and laboratory differences between genotypes did not affect survival of patients with chronic hepatitis B, regardless of lamivudine therapy. © 2013 Elsevier B.V.
